The transcriptome-wide association studies (TWAS) that test for association between the study 28 trait and the imputed gene expression levels from cis-acting expression quantitative trait loci (cis-29 eQTL) genotypes have successfully enhanced the discovery of genetic risk loci for complex traits.
The prior distribution deviates from the DP with base distribution as an Inverse Gamma (IG) 138 distribution and concentration parameter . Note that ? " can be viewed as a latent variable and 139 integrating out ? " will induce a nonparametric prior distribution on A , which is equivalent to a DP 140 normal mixture model [26] [27] [28] , P~( 1, ) .
Equation 3 142
Here, the nonparametric prior distribution on A is equivalently represented by a mixture normal 143 prior that is a weighted sum of an infinitely number of normal distributions QNQ0, σ a " R, = 0, … , + ∞R, 
148
Generally, the hyper parameters P , P , 4 , 4 in the Inverse Gamma distributions can be 149 set as 0.1 and ( f , f ) in the Gamma distribution can be set as (1, 0.1) to induce non-informative 150 priors for ( P " , 4 " , ). That is, the parameters ( P " , 4 " , ) will be adaptively estimated from the data 151 and the nonparametric prior on A will be data-driven. The posterior estimates for can be 152 obtained by the MCMC 29 or variational Bayesian algorithm 28; 40 , from the following joint conditional 
156
Particularly, the variational Bayesian algorithm 28; 40 is an approximation for the MCMC 29 with Elastic-Net and BSLMM Methods
162
The Elastic-Net model 17 (used by PrediXcan 11 ) estimates the cis-eQTL effect-sizes 9 in 163 Equation 1 with a combination of $ (LASSO) 19 and " (Ridge) 20 penalties by 164 9 = argmin wx − x " " + m ‖ ‖ $ + 1 2 (1 − )‖ ‖ " " o} ,
165
where ‖•‖ " denotes " norm, ‖•‖ $ denotes $ norm, ∈ [0, 1] denotes the proportion of $ 166 penalty, and denotes the penalty parameter. Particularly, PrediXcan 11 takes = 0.5 and tunes 167 the penalty parameter by a 5-fold cross validation. (1 − )‖ ‖ " " ‡o. Whereas, the BSLMM 18 assumes a mixture of two normal as 171 the prior for cis-eQTL effect-sizes, A~( 0, ( $ " + " " )) + (1 − ) (0, " " ). That is, the BSLMM 18 172 assumes all cis-SNPs have at least a small effect, which are normally distributed with variance 173 " " , and some proportion ( ) of cis-SNPs have an additional effect, normally distributed with 174 variance $ " . Particularly, with " " = 0, BSLMM becomes BVSR 22 , and with = 0, the BSLMM 175 becomes the LMM 23 . Therefore, the DP normal mixture [26] [27] [28] gene ABCA7 (see Figure S1 for the LD block structure) were used to simulate gene expression 225 levels.
226
We performed comprehensive scenarios that varied the proportion of causal SNPs (out of arbitrarily with respect to expression heritability such that the follow-up association study power 233 fell within the range of (25%, 85%). We also considered various training sample sizes (100, 300, 234 499) for simulation scenario with ¨©ª«©Z = 0.2 and Qℎ ‰ " , ℎ -" R = (0.2, 0.25).
235
With genotype matrix of the randomly selected causal SNPs (according to ¨©ª«©Z ), we 236 generated effect-sizes A from (0, 1) and then re-scaled the effect-sizes to ensure the targeted 237 ℎ ‰ " . Gene expression levels were generated by = + , with ~(0, (1 − ℎ ‰ " )). Then the 238 phenotype values were generated by = + , where was selected with respect to ℎ -" and 239 ~(0, (1 − ℎ -" )).
240
For each scenario, we repeated simulations for 1,000 times, where we applied both 241 PrediXcan 11 and DPR methods to obtain imputation models with training samples, impute the
242
GReX for test samples, and then conduct follow-up association studies using the imputed GReX.
243
We did not compare with FUSION 12 using BSLMM because of the computational burden of 244 estimating cis-eQTL effect-sizes by MCMC (~2 hours per gene). The association study power 245 was calculated as the proportion of 1,000 repeated simulations with p-value < 2.5 × 10 [²
246
(genome-wide significance threshold adjusting for testing 20K independent genes). higher imputation " in test data ( Figure 1A ). For example, when ¨©ª«©Z = 0.2, the average 274 imputation " of 1,000 simulations was estimated as 4.54% by using DPR versus 2.64% by using
275
PrediXcan with ℎ ‰ " = 0.1, while the average imputation " was estimated as 12.02% by using 276 DPR versus 9.13% by using PrediXcan with ℎ ‰ " = 0.2 (Table 1) . When ¨©ª«©Z = 0.01 , DPR
277
performed similarly as PrediXcan with ℎ ‰ " = (0.2, 0.5) but slightly out-performed PrediXcan with 278 ℎ ‰ " = (0.05, 0.1) (Table 1, Figure 1 ).
Consequently, when ¨©ª«©Z > 0.01 and ℎ ‰ " < 0.5 , or ¨©ª«©Z = 0.01 and ℎ ‰ " < 0.2 , the 280 power of association studies was higher by using DPR versus using PrediXcan imputation models 281 ( Figure 1B ). When ℎ ‰ " = 0.5 , using both imputation models led to comparable power for 282 association studies ( Figure 1B ). Even though both methods had similar over-estimated training 283 " (Figure S2 ), the DPR method still resulted in higher imputation " for test data (Table 1; 284 Figures 1A) and higher power for association studies ( Figure 1B ). In addition, from the simulation 302 ends were used in the imputation models as predictors.
303
In this real study, we compared transcriptome-wide 5-fold cross validation (CV) regression 304 " estimated by using both DPR and PrediXcan methods. Specifically, we randomly split 499 305 training samples into 5 folds, where the imputation " of each fold was calculated using the model 306 trained with the other 4 folds samples. If the training model is null, we take the imputation " as 307 0 and take the average imputation " across all 5-fold test samples as 5-fold CV " . The 308 transcriptome-wide median of 5-fold CV " is 0.013 by DPR versus 0.005 by PrediXcan. The 5-
309
fold CV " was used as the criterion for selecting significant imputation models ( " > 0.01 as 310 used by previous studies 11; 46 ). From Figure 3A , we can see that the DPR method obtained more 311 imputation models and higher imputation " when 5-fold CV " is in the range of (0.01, 0.05),
312
which is also consistent with our simulation studies. Overall, the DPR method obtained significant 313 imputation models for 8,742 genes versus 5,547 genes by PrediXcan (with 57.6% increases).
314
Thus, the DPR method featuring data-driven nonparametric prior for the cis-eQTL is preferred in 315 real studies for identifying more genes with imputable expression levels.
316
Next, we used all 499 training samples to fit imputation models for genes with respective 317 5-fold CV " > 0.01 by both DPR and PrediXcan, and then used these models to impute the 
326
( Figure S3A and Figure S4A ). Moreover, the multivariate phenotype association studies (Methods)
327
for both AD pathology indices also identified TRAPPC6A as the most significant gene with p-value 5.81 × 10 [² and FDR 0.08 ( Figure 3C ). On the other hand, the PrediXcan failed to obtain a 329 transcriptomic imputation model for TRAPPC6A ( Figure S3B , Figure S4B , and Figure S6 ).
330
Quantile-Quantile plots for these TWAS p-values were presented in Figure S5 .
331
In addition, for 14 known common and rare loci of late-onset AD 34-38 with significant 332 imputation models, we conducted association studies using transcriptomic imputation models 333 (DPR and PrediXcan) fitted from ROS/MAP data and standard GWAS results from IGAP 34 . Using 334 the imputation models fit by DPR, we identified 3 significant loci with FDR < 0.05 ( Figure 3B ) --
335
ADAM10, CD2AP, and TREM2 --that potentially affect late-onsite AD risk through transcript 336 abundance. Here, TREM2 was also identified by using the PrediXcan imputation model ( Figure   337 3B). Particularly, the PrediXcan method only imputed GReX for 5 out of these 14 loci. In summary,
338
these results show that the DPR method has superior power for follow-up TWAS.
340

Discussion
341
In this paper, we propose an improved nonparametric Bayesian method for transcriptomic 342 data imputation, accompanied with an integrated tool (freely available on GITHUB) that is referred 343 as 
368
As observed in the real ROS/MAP studies, there remains a large gap between the 5-fold 369 CV " using cis-eQTL predictors (~5%) and the average genome-wide heritability of gene 370 expression levels (21.8% estimated by GCTA 48 based on a LMM). This is likely due to the large 371 trans-acting contribution to transcript abundance documented for most genes. Thus, we 372 hypothesize that it is promising to further improve the imputation " by fitting transcriptomic 
376
Another limitation of existing TWAS methods is that the uncertainty of cis-eQTL effect-size 377 estimates has not been taken into accounted in the association studies. A Bayesian framework can also be derived by taking the standard errors of these cis-eQTL effect-size estimates as prior 379 standard deviations, which is part of our continuing research.
380
Besides the follow-up gene-based association studies (i.e., TWAS) described in this paper,
381
the transcriptomic imputation models can be further extended by incorporating environmental 382 contributions. The imputed transcript abundance levels can then be used for gene network 383 analysis, differential gene expression analysis, and transcriptome mediation analysis with GWAS 384 data. Validation of transcriptomic prediction accuracy in independent datasets will be critical in 385 this regard, but unfortunately multiple large and similar datasets are not yet generally available 386 for tissues other than peripheral blood.
387
In conclusion, we expect our work will provide a convenient and improved tool for 388 transcriptomic imputation using the currently available rich reference datasets, as well as 389 enhanced gene mapping for better understanding the genetic etiology of complex traits. associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. 432
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